908 Devices Inc Stock News

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-...

908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year.

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety cr...

WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technolo...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences. TD Cowen 45th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 5 at 9:50 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Tue...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the fourth quarter and full year 2024 before market open on Tuesday, March 4, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio ...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024. Preliminary unaudited revenue for the fourth quarter of 2024 is expected to be approximately $17.2 million, compared to $14.4 million in the fourth q...

BOSTON--(BUSINESS WIRE)-- #automation--Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge's bioreactors with 908 Devices' MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the ne...